SRNE - Sorrento Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1500
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.1500
Open3.1500
Bid0.0000 x 3100
Ask0.0000 x 900
Day's Range3.1100 - 3.3900
52 Week Range1.8000 - 7.5500
Volume1,166,926
Avg. Volume2,438,596
Market Cap362.196M
Beta (3Y Monthly)3.10
PE Ratio (TTM)N/A
EPS (TTM)-2.4170
Earnings DateMay 23, 2019 - May 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)

    SAN DIEGO, June 14, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences.

  • GlobeNewswire5 days ago

    Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company

    Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding Company. No decisions have been taken at this point on the structure or timing of any initial public offering, and no assurance can be given that an initial public offering will be pursued or completed. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

  • GlobeNewswire7 days ago

    Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of resiniferatoxin as a local nerve block injection for the control of neuropathic post-amputation residual limb pain in humans. The population of “aging amputee cats” living with the sequalae of surgeries performed years ago is quite large making it a valuable “model” when looking at residual limb pain which affects about 30% of the 1.6 million American amputees, or phantom limb pain which affects up to 70% of those human patients1.

  • GlobeNewswire12 days ago

    Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration

    Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (SRNE), announces the completion of post-merger integration. Following the merger with Semnur Pharmaceuticals, Inc. in March 2019, and the contribution of Scilex Pharmaceuticals Inc. equity to Scilex Holding Company, Scilex rapidly proceeded to implement key changes necessary to ensure the long-term success of the newly formed company. Gross sales in the past three months have shown strong and sustained month-over-month growth, increasing from approximately $1 million in March, to $2.4 million in April and $3.3 million in May, respectively.

  • GlobeNewswire13 days ago

    Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships

    SAN DIEGO, June 04, 2019 -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd..

  • Why Sorrento Therapeutics Is Getting Crushed Today
    Motley Fool19 days ago

    Why Sorrento Therapeutics Is Getting Crushed Today

    The biopharma stock is continuing to experience volatility today.

  • GlobeNewswire27 days ago

    Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).

    SAN DIEGO, May 21, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB.

  • Options Traders Expect Huge Moves in Sorrento (SRNE) Stock
    Zacks28 days ago

    Options Traders Expect Huge Moves in Sorrento (SRNE) Stock

    Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

  • What's in Store for Sorrento (SRNE) This Earnings Season?
    Zackslast month

    What's in Store for Sorrento (SRNE) This Earnings Season?

    Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

  • ACCESSWIRE2 months ago

    Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc.

    HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. ...

  • GlobeNewswire2 months ago

    Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions.

  • Why Sorrento Therapeutics Is Jumping Today
    Motley Fool2 months ago

    Why Sorrento Therapeutics Is Jumping Today

    Good news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs.

  • GlobeNewswire2 months ago

    Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study aimed at exploring potential benefits of resiniferatoxin in controlling neuro-inflammatory processes associated with Parkinson’s disease in a rodent model. Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. Transient receptor potential vanilloid 1 (TRPV1) is involved in pain perception and is highly expressed in sensory neurons.

  • Here's Why Sorrento Therapeutics Soared 134% in March
    Motley Fool2 months ago

    Here's Why Sorrento Therapeutics Soared 134% in March

    The early-stage biotech jumped without any significant news.

  • Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme
    American City Business Journals2 months ago

    Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme

    Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch and kill” plan that ultimately blocked the release of Sorrento’s new cancer drug.

  • Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?
    Zacks2 months ago

    Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?

    Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.

  • GlobeNewswire3 months ago

    Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

    Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. All subjects experienced rapid reduction of leg and back pain following two SP-102 injection treatments, with group median for average pain in affected leg reduced over 50% throughout 28 days for each injection (100% response rate). Scilex expects SP-102 to be the first FDA approved non-opioid epidural injections for sciatica with the potential to replace the current 10 to 11 million off-label epidural steroid injections administered each year in the U.S.

  • Analysts Give Favorable Opinions on Sorrento Therapeutics
    Market Realist3 months ago

    Analysts Give Favorable Opinions on Sorrento Therapeutics

    How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 295.22% for Sorrento Therapeutics (SRNE) based on the stock’s

  • Sorrento Therapeutics News: Why SRNE Stock Is On The Move
    InvestorPlace3 months ago

    Sorrento Therapeutics News: Why SRNE Stock Is On The Move

    Recent Sorrento Therapeutics news has SRNE stock on a roller coaster ride today.Source: Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals is merging with Semnur Pharmaceuticals. This merger has the two companies coming together in an effort to create a leader in the non-opioid pain medicine market. The new company's name is Scilex Holding CompanyThe Sorrento Therapeutics news means that the company's stake in Scilex Pharmaceuticals is being converted into a new stake at the combined company. This has its 77% stake in Scilex Pharmaceuticals becoming a 58% stake in Scilex Holding Company.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"This transaction is highly synergistic," Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, said in a statement. "Scilex has built up a commercial organization with over 100 highly experienced sales representatives, fully staffed marketing, market access, and medical liaison teams while Semnur has a very exciting Phase 3 compound in non-opioid pain management."Scilex Pharmaceuticals' ZTlido is already performing well in the early months of its commercial release. Semnur also has a compound that is in a Phase 3 trial and could also be a strong win for the newly-merged company. * 7 Beaten-Up Stocks to Buy as They Reverse Course The Sorrento Therapeutics news today has SRNE stock on a wild ride. It started off up up 8% on Friday morning and reached a peak increase of 24% during morning trading. However, the stock is now down 9% as of Friday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Sorrento Therapeutics News: Why SRNE Stock Is On The Move appeared first on InvestorPlace.

  • GlobeNewswire3 months ago

    Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

    Sorrento Therapeutics, Inc. (SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals Inc. (Scilex) has closed a transaction to merge with Mountain View, California, based Semnur Pharmaceuticals, Inc. (Semnur) to form a new company, Scilex Holding Company (Scilex Holding). Sorrento’s equity stake in Scilex (77%) has been converted into a 58% stake in Scilex Holding. With Scilex’s lead product ZTlido® (lidocaine topical system 1.8%) ramping rapidly in the early months of commercial launch and Semnur’s lead compound (non-opioid corticosteroid gel) in Phase 3 pivotal studies for the treatment of lumbar radicular pain/sciatica with Fast Track status from the FDA, Scilex Holding is well positioned to become a global leader in non-opioid pain management.

  • GlobeNewswire3 months ago

    Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

    Yuhan) and Sorrento Therapeutics, Inc. (SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, suppressing the inhibitory signal to T cells and enhancing the killing effect of T cells on tumors.

  • GlobeNewswire4 months ago

    Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

    SAN DIEGO, Feb. 25, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that senior management will provide a corporate overview at the upcoming.

  • GlobeNewswire4 months ago

    Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

    The proceeds of the transaction will be utilized to advance ImmuneOncia’s Phase I and II clinical studies of IMC-001, a PD-L1 monoclonal antibody, as well as to support its earlier stage programs. As a result of this financing, ImmuneOncia is expected to be sufficiently funded in preparation for an initial public offering, which is expected to occur in 2021.